{"title":"Long-Term Fatigue Following Transient Ischemic Attack: A Prospective Cohort Study.","authors":"Birgitte Hede Ebbesen,Simon Grøntved,Jakob Nebeling Hedegaard,Søren P Johnsen,Jane Andreasen,Krystian Figlewski,Mirko Porobic,Michael Skovdal Rathleff,Boris Modrau","doi":"10.1212/wnl.0000000000213605","DOIUrl":null,"url":null,"abstract":"BACKGROUND AND OBJECTIVES\r\nBy definition, patients with transient ischemic attack (TIA) should not have residual symptoms beyond 24 hours. However, preliminary evidence indicates lasting challenges such as fatigue. It is unknown who develops fatigue, and the extent. This knowledge is required to develop evidence-based support for patients. We aimed to explore fatigue up to 12 months after TIA and determine what characterizes patients who experience pathologic fatigue.\r\n\r\nMETHODS\r\nThis is a prospective cohort study including patients with TIA diagnosed at a specialized stroke unit. Fatigue was measured using Multidimensional Fatigue Inventory (MFI-20) and Fatigue Severity Scale at 14 days (baseline) and 3, 6, and 12 months after discharge. The association between candidate prognostic factors and fatigue at 12 months was tested using linear regression models. We compared model performances using likelihood ratio (LR).\r\n\r\nRESULTS\r\nWe included 354 patients, of which 287 provided baseline responses (mean age 70.0 ± 11.1, 42.5% female). At baseline and 3, 6, and 12 months, the mean level of general fatigue on MFI was 12.3 ± 4.6, 11.9 ± 4.6, 11.4 ± 4.5, and 11.1 ± 4.5 and the proportion with pathologic fatigue (≥12 on the MFI-20 General Fatigue) was 61.3%, 53.5%, 54.0%, and 53.8%, respectively. The prevalence of acute infarction was evenly distributed between patients who reported fatigue and those who did not. Previous anxiety/depression was twice as common in the group that reported fatigue. The model including baseline level of fatigue, sex, age, and acute infarction was able to explain variability in the reported data to a statistical significantly higher extent, compared with the model only including sex, age, and acute infarction (p < 0.001, LR = 387.30).\r\n\r\nDISCUSSION\r\nPathologic fatigue is common up to 12 months after TIA diagnosis. If patients report fatigue within 14 days after discharge, it is likely that this remains until 12 months. We found no indication of an association between the presence of acute ischemic lesions and fatigue. The prevalence of previous anxiety/depression was higher in the group that reported fatigue.\r\n\r\nTRIAL REGISTRATION INFORMATION\r\nThe study is part of the Life After Stroke Cohort (ClinicalTrials.gov: NCT05234528). Registered February 1, 2022. First patient included February 2, 2022.","PeriodicalId":19256,"journal":{"name":"Neurology","volume":"11 1","pages":"e213605"},"PeriodicalIF":7.7000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/wnl.0000000000213605","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND AND OBJECTIVES
By definition, patients with transient ischemic attack (TIA) should not have residual symptoms beyond 24 hours. However, preliminary evidence indicates lasting challenges such as fatigue. It is unknown who develops fatigue, and the extent. This knowledge is required to develop evidence-based support for patients. We aimed to explore fatigue up to 12 months after TIA and determine what characterizes patients who experience pathologic fatigue.
METHODS
This is a prospective cohort study including patients with TIA diagnosed at a specialized stroke unit. Fatigue was measured using Multidimensional Fatigue Inventory (MFI-20) and Fatigue Severity Scale at 14 days (baseline) and 3, 6, and 12 months after discharge. The association between candidate prognostic factors and fatigue at 12 months was tested using linear regression models. We compared model performances using likelihood ratio (LR).
RESULTS
We included 354 patients, of which 287 provided baseline responses (mean age 70.0 ± 11.1, 42.5% female). At baseline and 3, 6, and 12 months, the mean level of general fatigue on MFI was 12.3 ± 4.6, 11.9 ± 4.6, 11.4 ± 4.5, and 11.1 ± 4.5 and the proportion with pathologic fatigue (≥12 on the MFI-20 General Fatigue) was 61.3%, 53.5%, 54.0%, and 53.8%, respectively. The prevalence of acute infarction was evenly distributed between patients who reported fatigue and those who did not. Previous anxiety/depression was twice as common in the group that reported fatigue. The model including baseline level of fatigue, sex, age, and acute infarction was able to explain variability in the reported data to a statistical significantly higher extent, compared with the model only including sex, age, and acute infarction (p < 0.001, LR = 387.30).
DISCUSSION
Pathologic fatigue is common up to 12 months after TIA diagnosis. If patients report fatigue within 14 days after discharge, it is likely that this remains until 12 months. We found no indication of an association between the presence of acute ischemic lesions and fatigue. The prevalence of previous anxiety/depression was higher in the group that reported fatigue.
TRIAL REGISTRATION INFORMATION
The study is part of the Life After Stroke Cohort (ClinicalTrials.gov: NCT05234528). Registered February 1, 2022. First patient included February 2, 2022.
期刊介绍:
Neurology, the official journal of the American Academy of Neurology, aspires to be the premier peer-reviewed journal for clinical neurology research. Its mission is to publish exceptional peer-reviewed original research articles, editorials, and reviews to improve patient care, education, clinical research, and professionalism in neurology.
As the leading clinical neurology journal worldwide, Neurology targets physicians specializing in nervous system diseases and conditions. It aims to advance the field by presenting new basic and clinical research that influences neurological practice. The journal is a leading source of cutting-edge, peer-reviewed information for the neurology community worldwide. Editorial content includes Research, Clinical/Scientific Notes, Views, Historical Neurology, NeuroImages, Humanities, Letters, and position papers from the American Academy of Neurology. The online version is considered the definitive version, encompassing all available content.
Neurology is indexed in prestigious databases such as MEDLINE/PubMed, Embase, Scopus, Biological Abstracts®, PsycINFO®, Current Contents®, Web of Science®, CrossRef, and Google Scholar.